Normando Iznaga

TL;DR: A controlled, double blind, randomized clinical trial was conducted in 106 advanced squamous cell carcinoma of the head and neck patients, mostly, unfit for chemo-radiotherapy, and a trend towards survival benefit for nimotuzumab treated subjects was found.

TL;DR: An explanation is suggested for nimotuzumab clinical profile, whereby antitumor activity is obtained in absence of severe toxicities due to its properties of bivalent binding to EGFR.

TL;DR: Pharmacokinetic analysis revealed that elimination half-lives and the AUC increased linearly with dose, while total body clearance decreased when increasing doses of h-R3, and Qualitative analysis of whole-body images showed that the liver had the highest mAb uptake, and no relation between shed EGFR and mAb clearance was found.

TL;DR: A clinical trial was conducted in brain tumor patients to evaluate toxicity, immunogenicity, and clinical benefit of escalating doses of ior egf/r3 MAb, and no significant toxicity was found, except in one patient who developed a grade 4 allergic adverse event.

TL;DR: The pharmacodynamic data confirmed the ability of nimotuzumab to decrease EGFR phosphorylation, and downstream effects were observed in tumor cells but not in skin, a finding that may help to explain the lack of skin rash in patients treated with nimzumab.